Former U.S. House Speaker Newt Gingrich (R-GA) extolled the therapeutic promise of ibogaine on a recent episode of his podcast, drawing attention to a Stanford University study that found the psychedelic showed potential to treat PTSD, anxiety and depression in military veterans with traumatic brain injury.
“This could be one of the great breakthroughs of the next 10 or 15 years,” he said on the episode of Newt World that aired last month.
Gingrich, who previously had the executive director of Americans for Ibogaine as a guest on his show, highlighted top-level findings of the 2024 paper, such as an observed 88 percent reduction in PTSD, an 87 percent reduction in depression and an 81 percent reduction in anxiety in participants one month after treatment.
Former U.S. House Speaker Newt Gingrich (R-GA) extolled the therapeutic promise of ibogaine on a recent episode of his podcast, drawing attention to a Stanford University study that found the psychedelic showed potential to treat PTSD, anxiety and depression in military veterans with traumatic brain injury.
“This could be one of the great breakthroughs of the next 10 or 15 years,” he said on the episode of Newt World that aired last month.
Gingrich, who previously had the executive director of Americans for Ibogaine as a guest on his show, highlighted top-level findings of the 2024 paper, such as an observed 88 percent reduction in PTSD, an 87 percent reduction in depression and an 81 percent reduction in anxiety in participants one month after treatment.
Marijuana Consumers Have “Significantly Decreased Odds” Of Cognitive Decline
“The future of healing,” the former speaker wrote on social media, “may lie in an ancient plant.”
The episode’s guest was Nolan Williams, a study co-author and professor of psychiatry and behavioral science at Stanford, who explained some of the paper’s main findings and fielded questions from Gingrich.
Read the rest of this story at Marijuana Moment
